Today, Chris covers Gilead’s remdesevir pricing, the winners in a cashless society, and how PG&E will emerge from bankruptcy.
Topics discussed:
<ol><li>Gilead Science’s Remdesevir Pricing</li>
<li>The Cashless Society</li>
<li>PG&E’s Bankruptcy Exit</li>
</ol>Links mentioned in this episode:
<ul><li>invstr.com/the-cost-of-a-cure</li>
<li>invstr.com/the-cashless-society-accelerates</li>
<li>invstr.com/01-july-watchlist-2</li>
</ul>

Today, Chris covers Gilead’s remdesevir pricing, the winners in a cashless society, and how PG&E will emerge from bankruptcy. Topics discussed: Gilead Science’s Remdesevir Pricing The Cashless Society PG&E’s Bankruptcy Exit Links mentioned in this episode: invstr.com/the-cost-of-a-cure invstr.com/the-cashless-society-accelerates invstr.com/01-july-watchlist-2

Today, Chris covers Gilead’s remdesevir pricing, the winners in a cashless society, and how PG&amp;E will emerge from bankruptcy.
Topics discussed:
<ol><li>Gilead Science’s Remdesevir Pricing</li>
<li>The Cashless Society</li>
<li>PG&amp;E’s Bankruptcy Exit</li>
</ol>Links mentioned in this episode:
<ul><li>invstr.com/the-cost-of-a-cure</li>
<li>invstr.com/the-cashless-society-accelerates</li>
<li>invstr.com/01-july-watchlist-2</li>
</ul>

The Cost of a Cure

A bite-sized finance and investing podcast to help you become a better investor. The biggest stories of the day, told in 3 minutes. Perfect for on the go or on the couch.

Share The Cost of a Cure

Sign up to save your podcasts

The Cost of a Cure

The Cost of a Cure